Skip to main content

What the FDA labels say about taking them together

Nelfinavir and rosuvastatin

Nelfinavir's FDA label of December 11, 2025 names rosuvastatin in its drug interactions section; the rosuvastatin labels PlainMeds reads (2) do not name nelfinavir. The nelfinavir label: “Titrate atorvastatin dose carefully and use the lowest necessary dose; do not exceed atorvastatin 40 mg/day.”

Check it at the source: the nelfinavir FDA label on DailyMed (effective December 11, 2025, AGOURON); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).

What does the nelfinavir label say about rosuvastatin?

Nelfinavir label, drug interactions

Concomitant Drug Class/Drug Name: Atorvastatin Rosuvastatin; Effect on Concentration: ↑ atorvastatin ↑ rosuvastatin; Clinical Comment: Titrate atorvastatin dose carefully and use the lowest necessary dose; do not exceed atorvastatin 40 mg/day.

Source: FDA drug label (VIRACEPT), AGOURON, effective December 11, 2025 (SPL set e72c2bc6-9462-4a2e-8e1d-b97592376cbd), via openFDA; the full label on DailyMed

What does the rosuvastatin label say about nelfinavir?

Rosuvastatin's label (effective September 4, 2026) and its 1 other brand-application label do not name nelfinavir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Nelfinavir generic labelers
45Rosuvastatin generic labelers
NelfinavirRosuvastatin
Labeled forHIVHeart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$0.0692 per tablet 40 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?